Share this video  

WCLC 2023 | Poziotinib in pretreated patients with HER2 exon 20 insertion NSCLC

Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares findings from a study which focuses on HER2 exon 20 mutations in non-small cell lung cancer (NSCLC) and the potential for poziotinib as a treatment option after patients have received at least two lines of systemic therapy, including platinum-based regimens. Trastuzumab deruxtecan (T-DXd) is currently the only approved therapy for these patients as a second-line option. Poziotinib is a potent tyrosine kinase inhibitor targeting EGFR and HER2 exon 20 mutations, and it is being studied in a Phase II ZENITH20 trial (NCT03318939). The study suggests that poziotinib could be a valuable treatment option for HER2 exon 20 mutations in NSCLC patients who have limited alternatives after previous treatments. Additionally, no new safety concerns were identified in this patient population. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.